6 Vision Therapy Myths, Checked Against Evidence

Vision therapy tends to get one of two reactions: enthusiastic recommendation, or flat dismissal. Neither one helps a parent who is trying to decide what to do next.

So here is our starting position at Vision & Learning Center. Vision therapy is not “highly effective” as a blanket statement, and we no longer describe it that way. It is well supported for some diagnoses, weakly supported for others, and not a treatment at all for several problems it sometimes gets offered for. The honest answer always depends on the condition being treated.

Below are the six myths we hear most often, each checked against the published research, including the studies that did not go our profession’s way. For the fuller picture, see what vision therapy is and our honest evidence summary.

Key takeaways

• The strongest evidence is for symptomatic convergence insufficiency in children, where supervised office-based therapy clearly beat placebo therapy.
• The clearest negative result is reading. The largest trial found therapy no better than placebo for reading comprehension, so we do not claim it raises reading scores.
• Professional bodies genuinely disagree. Pediatrics and ophthalmology reject vision therapy for learning disabilities; optometry holds that vision problems interfere with learning.
• For refractive error and amblyopia, glasses, patching and atropine remain first-line. Therapy does not replace them.
• The major trials ran 12 to 16 weeks, with weekly office visits plus home reinforcement. That is a useful benchmark, not a promise.

Myth 1: Vision therapy is just eye exercises you could do at home

What the research shows. The Convergence Insufficiency Treatment Trial (CITT) compared four approaches head to head in 221 children aged 9 to 17. After 12 weeks, a successful or improved outcome was reached by 73% with supervised office-based vergence and accommodative therapy plus home reinforcement, 43% with home pencil push-ups, 33% with home computer therapy plus pencil push-ups, and 35% with office-based placebo therapy (CITT Study Group, 2008). A Cochrane network meta-analysis of 12 trials reached the same conclusion: office-based therapy with home reinforcement outperformed both home push-ups and home computer therapy with push-ups (Scheiman et al., 2020).

The delivery is not incidental. What separates a therapy program from an exercise handout is measurement, supervision, and a demand that gets harder as the child improves. Home practice matters too, but as reinforcement of what was set in the office, not as a substitute for it.

Myth 2: It is only for children with severe vision problems

What the research shows. The binocular and focusing problems vision therapy targets are common, and they are easy to miss because ordinary sight testing does not look for them. In a school-based US study, about 13% of fifth- and sixth-graders met a high-suspect or definite convergence insufficiency classification (Rouse et al., 1999). And these problems travel together: 74% of the children in CITT with symptomatic convergence insufficiency also had an accommodative (focusing) dysfunction (Scheiman et al., 2011).

Standard screenings are not built to find them. The American Optometric Association’s pediatric guideline summarises research in which acuity testing alone missed 75.5% of children later found on a complete examination to have binocular and eye-movement problems (AOA, 2017).

One caveat we want to be clear about: common does not mean every child needs therapy. Treatment decisions in these trials rested on measured clinical signs plus symptoms, and so should ours.

Myth 3: Glasses or surgery are the only real treatments

What the research shows. This one is partly right, and which part depends entirely on the diagnosis.

• Refractive error (nearsightedness, farsightedness, astigmatism) is corrected with glasses or contacts. Vision therapy does not change a prescription, and we will not suggest that it does.

• Amblyopia (“lazy eye”) is treated with the correct glasses first, then patching or atropine drops.

  Patching and atropine produced comparable improvement in a 419-child randomized trial (PEDIG, 2002). Binocular and dichoptic digital treatments are an active research area, but the American Academy of Ophthalmology reviewed 20 studies and found no level I evidence supporting them as a substitute for patching or optical correction (Pineles et al., 2020). A later pivotal trial of a dichoptic digital therapeutic did improve acuity 1.8 lines versus 0.8 lines with glasses alone. The comparator there was glasses, not patching (Xiao et al., 2022).

• Convergence insufficiency is where lenses alone fall short. Base-in prism reading glasses did no better than placebo reading glasses in 72 children (Scheiman et al., 2005), while office-based therapy beat placebo in CITT.

Myth 4: Vision therapy is not supported by science

This is the myth that deserves the longest answer, because the honest reply is neither “yes it is” nor “no it isn’t.” It is: supported for what?

Where the evidence is strong

For symptomatic convergence insufficiency in children, office-based vergence and accommodative therapy — the vision therapy we provide — is the best-supported treatment available. The Cochrane review put it at roughly three times the likelihood of a successful outcome compared with placebo therapy in children (Scheiman et al., 2020). Among children who became asymptomatic after office-based therapy, 84.4% were still asymptomatic a year later (CITT Study Group, 2009). Accommodative amplitude improved 9.9 dioptres with office-based therapy versus 2.2 with placebo (Scheiman et al., 2011).

Where the evidence is negative or thin

• Reading. CITT-ART enrolled 310 children with symptomatic convergence insufficiency and measured reading comprehension after 16 weeks: therapy improved scores 3.7 points, placebo therapy 3.8 (CITT-ART Investigator Group, 2019). This was the biggest and best-designed test of the reading question, and it was negative.
• Symptoms in that same trial. Clinical signs improved more with therapy (near point of convergence 10.4 vs 6.2 cm; fusional vergence 23.2 vs 8.8 prism dioptres), but symptom scores improved about the same in both groups (CITT-ART Investigator Group, 2019). CITT 2008 and CITT-ART 2019 belong in the same sentence, always.
• Adults. The adult evidence is small: in one trial, symptom-elimination criteria were met by 42% with therapy and 31% with placebo, and more than half of the treated adults remained symptomatic (Scheiman et al., 2005).
• Learning disorders. Therapy improved binocular vision measures in children with specific learning disorders, but the outcomes measured were binocular, not academic (Hussaindeen et al., 2018).

Where the professions disagree

The joint statement from the American Academy of Pediatrics, the American Academy of Ophthalmology, AAPOS and AACO holds that dyslexia is language-based, that vision problems do not cause it, and that eye exercises, behavioral vision therapy and tinted lenses are not endorsed for learning disabilities (AAP/AAO/AAPOS/AACO, 2009; technical report, 2011; reaffirmed 2014). The optometric position statement holds that vision problems can and often do interfere with learning, and frames optometric care as one part of a multidisciplinary approach (AAO/AOA, 1997).

Our clinical perspective. We agree with both bodies where they agree, which is more than the debate suggests. Vision problems do not cause dyslexia, and vision therapy is not a treatment for dyslexia. What we treat are binocular and focusing problems that make near work uncomfortable and tiring. If a child also needs reading instruction, they need reading instruction, and we say so.

Myth 5: It takes too long to see results

What the research shows. The trials give real benchmarks. CITT ran 12 weeks and CITT-ART ran 16 weeks, both with weekly office visits plus home reinforcement (2008; 2019). Durability was reasonable in responders: 84.4% still asymptomatic at one year, and reduced accommodative amplitude had recurred in only 12.5% (2009; 2011).

Real programs vary with the diagnosis, the child’s age, other conditions in the picture, and how consistently home work actually gets done. Before you start anything, ask for the expected number of weeks and how progress will be measured. We go through this in how long vision therapy takes.

Myth 6: It is expensive and not worth it

Cost is a fair question, and “it’s worth it” is not an answer. The better question is worth it for what, and how will we know?

At our offices the evaluation and the therapy program are priced separately, so you get a diagnosis and a plan before you commit to a program. We are an out-of-network provider, which means payment is due at the time of service. If a medical diagnosis is found during the evaluation, we provide the procedure and diagnosis codes so you can submit them to your plan for possible out-of-network reimbursement; on vision plans we are an open-access provider for comprehensive eye exams. Our cost and price page lists the questions worth asking your insurer before you start, and what changes the price of vision therapy covers what moves the number.

Before saying yes to any program, anywhere, ask five things: What is the diagnosis? What does the evidence show for that specific diagnosis? How many weeks? How will progress be measured? What happens if the measurements do not move? A practice that cannot answer those has not earned the fee. More questions like these are answered on our FAQ page.

Where to go from here

Most of these myths persist because the real answer is conditional, and conditional answers travel badly. Vision therapy has good evidence behind it for particular binocular and focusing diagnoses, thin evidence in adults, and negative evidence for reading outcomes. Knowing which category your child falls into is the whole point of the evaluation.

If your child is struggling with near work, losing their place while reading, complaining of headaches or double vision, or avoiding homework in a way that does not look like ordinary reluctance, a comprehensive developmental vision evaluation will tell you whether a treatable visual problem is part of the picture. Schedule an evaluation or learn what our examinations include.